Vol. 4 No. 2 (2024): February
Reimbursement Reviews

Mirikizumab (Omvoh)

decorative image of the issue cover

Published February 9, 2024

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Mirikizumab (Omvoh) is available in 3 different dosing forms:
    • prefilled syringe — 100 mg/1 mL SC
    • autoinjector pen — 100 mg/1 mL SC
    • vial — 300 mg/15 mL IV.
  • Indication: For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, had a loss of response, or were intolerant to conventional therapy, a biologic treatment, or a Janus kinase inhibitor